GlaxoSmithKline (GSK) Plc’s breast cancer pill Tykerb, used with Roche Holding AG (ROG)’s drug Xeloda, helped treat the disease’s spread to the brain, according to a study.
The treatments shrank the size of brain tumors by at least 50 percent in two-thirds of the patients studied, according to a trial funded by London-based Glaxo and published today in the Lancet Oncology journal. The research included 45 women who have the HER2 gene and advanced stage breast cancer.